Eugene Braunwald, Whose Research Reshaped Cardiology, Dies at 96
Jonathan Kandell / nytimes - His work changed how doctors understood heart attacks, heart failure and coronary artery disease, and helped lead to therapies that saved millions of lives.
AI Summary: Eugene Braunwald, a towering figure whose research reshaped modern cardiology, has died at 96. Colleagues remember his seminal contributions to cardiac physiology, therapeutics, and clinical practice that set the stage for decades of advances. His passing marks the end of an era for a field he helped steer.
Introducing the Chairs at ISCO Congress 2026 – Part 1
oncodaily - International School of Clinical Oncology – ISCO shared a series of posts on Facebook, introducing the Chairs at the upcoming ISCO Congress 2026: 1. “We are delighted to welcome Prof. […]
AI Summary: The ISCO Congress 2026 has unveiled its chairpersons and session lineup, spotlighting leaders shaping the program and key scientific themes. Organizers framed the event as a platform for multidisciplinary exchange and translational oncology priorities, aiming to accelerate research-to-clinic progress while giving attendees plenty to talk about between coffee breaks.
- Leadership, training and career-development programs (4)
- Major trial takeaways across 2026 oncology congresses (4)
- Meet the ISCO 2026 Chairs and Honorees (6)
- Scientific tracks: AI, translational & cellular therapy (4)
- All Other Stories
Leadership, training and career-development programs
Major trial takeaways across 2026 oncology congresses
Meet the ISCO 2026 Chairs and Honorees
Scientific tracks: AI, translational & cellular therapy
All Other Stories
WHO approves first malaria treatment for infants
medicalxpress - The World Health Organization announced Friday that it had given prequalification approval to a malaria treatment for newborns and infants for the first time.
AI Summary: The World Health Organization has cleared the first malaria treatment specifically for infants, granting prequalification that paves the way for broader procurement and use in endemic countries. Regulators' sign-off targets a vulnerable age group long underserved by effective pediatric therapies, potentially speeding distribution through global health channels and donor programs.
A deep learning pathomics platform may help predict response to immunotherapy in lung cancer patients
medicalxpress - A biology-guided artificial intelligence model applied to routine pathology slides accurately predicted outcomes and response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC), according to a study presented at the American A…
AI Summary: Researchers developed a deep‑learning pathomics platform that analyzes routine histology to predict which lung cancer patients are likely to respond to immunotherapy. By extracting subtle morphological patterns invisible to the human eye, the tool promises to refine treatment selection and spare nonresponders unnecessary toxicity—assuming clinicians trust an algorithm more than their gut.
- AI pathomics flags immunotherapy responders in lung cancer (4)
- Challenges deploying AI in lung cancer diagnosis and care (3)
- Evolving lung cancer immunotherapy trials and biomarker debates (4)
- All Other Stories
AI pathomics flags immunotherapy responders in lung cancer
Challenges deploying AI in lung cancer diagnosis and care
Evolving lung cancer immunotherapy trials and biomarker debates
All Other Stories
Distribution of Phase I lung cancer trials may be consolidating at top-performing US sites
medicalxpress - Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly concentrated at the top 20 highest-volume clinical trial si…
AI Summary: A new analysis shows Phase I lung cancer trials are becoming concentrated at a relatively small number of leading U.S. centers, raising concerns about geographic inequity in access to early‑phase studies. The trend could speed drug development at elite sites while leaving patients in other regions with fewer experimental options and longer travel burdens.
- Conference highlights, care models and awareness (4)
- Consolidation at top U.S. Phase I centers (3)
- Early-phase trials and next-gen therapies (4)
- All Other Stories
Conference highlights, care models and awareness
Consolidation at top U.S. Phase I centers
Early-phase trials and next-gen therapies
All Other Stories
FDA backs 3 psychedelic drug studies for mental illness
Ella Ruder / beckershospitalreview - The FDA is issuing national priority vouchers to three companies studying psychedelic drugs to treat serious mental illness. The vouchers were issued to companies studying psilocybin for treatment-resistant depression and major depressive disorder as well…
AI Summary: The FDA announced a targeted push to accelerate clinical research into psychedelics for mental illness, issuing three commissioner vouchers to support rigorous trials of psychedelic therapies. The move aims to fast-track evidence generation under regulatory oversight, signalling growing agency willingness to explore unconventional treatments while keeping safety and trial standards squarely in view.
- FDA voucher push and federal policy shift (5)
- Psilocybin and brain science (4)
- Real-world use, safety and clinical readiness (3)
- All Other Stories